Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.
NCT ID: NCT05415787
Last Updated: 2024-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2022-08-18
2024-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney
NCT06214000
Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program
NCT01786031
Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer
NCT05333432
PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer
NCT04983459
PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
NCT04298112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adult patients with metastatic prostate cancer
Blood sample
2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
Urine sample
Urine sample is taken during the consultation carried out for the patient's care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
Urine sample
Urine sample is taken during the consultation carried out for the patient's care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic prostate cancer
* Archived tissue sample available for testing for somatic variants of HRR genes (including BRCA1/BRCA2)
* Free, informed and signed consent for research
* Refusal of blood and urine collection
* Patient cognitively incapable of signing consent to participate in this study
* Patient under guardianship or curatorship
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthias Tallegas
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Tours
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospital
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DR220119 PROMECI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.